Novartis Shelves Potential Drug After Failed Clinical Trial

Novartis has decided to shelve a potential blockbuster drug after a clinical trial described as groundbreaking ended in failure. This negative development in the company's development process revealed that the drug could not provide the targeted therapeutic benefit. The failure of the trial is considered a significant setback in Novartis's R&D portfolio. The drug was previously seen as a key element in the company's future growth strategy due to its high commercial potential. Company management halted the drug's late-stage development program because the trial results fell short of expectations. This decision is interpreted as part of Novartis's effort to redirect its resources to more promising projects. The failure of the clinical research once again highlights the nature of high-risk R&D investments in the pharmaceutical industry. Novartis stated that despite such setbacks, it will continue its work in innovative treatment areas. Not investment advice.

📊 NVS — Piyasa Yorumu

▼ down · 55%

Novartis's decision to shelve a drug following a failed clinical trial can be seen as a negative news flow in the short term. However, the stock price has risen 1.59% in the last 24 hours to 162.53, with an RSI of 51.7 in neutral territory, indicating that the market has not yet reacted sharply to the news. The MACD is below its signal line (0.24 vs 0.49) and the price is slightly below the SMA20, suggesting weak short-term momentum. The impact of the news may be limited to the cancellation of a single program; therefore, I paint a bearish but low-confidence picture. The SMA50 (161.65) should be monitored as support.

RSI 14

51.7

MACD

0.24

24h Δ

1.59%

Canlı Grafikler